Search Results

Hera Biotech is pleased to report the interim results for its proof-of-concept multi-center clinical trial of the MetriDx™ endometriosis diagnostic test.

Hera Biotech announced today that it has reached an agreement to acquire the endometriosis diagnostic assets and associated IP of single-cell and AI-driven biomarker discovery company Scailyte, creating an important consolidation of the only two tissue-based diagnostic programs for endometriosis.

Hera BioLabs, an innovative service and technology provider with novel genetic engineering products, has announced a collaboration with Charles River Laboratories, International Inc. for a global license agreement to commercialize Hera’s SRGTM rat (OncoRat®).

As the industry witnesses a surge in demand for innovative antibodies on prevalent research targets, Creative Biolabs is poised to meet and exceed these expectations with their comprehensive suite of services.

PRISM BioLab, Co. Ltd. announced that it has entered into a target-exclusive research and licensing agreement with ONO PHARMACEUTICAL CO., LTD.

NSG BioLabs announces a new partnership with Eppendorf, a leading international life science company that develops, manufactures, and distributes instruments, consumables, and services for use in laboratories around the world, to support biotech startups by providing needed resources such as product and applications expertise and its networks to advance startup research and development.